| 叶玉燕.黄葵胶囊联合缬沙坦和雷公藤多苷对早期糖尿病肾病患者临床研究[J].浙江中西医结合杂志,2020,30(3): |
| 黄葵胶囊联合缬沙坦和雷公藤多苷对早期糖尿病肾病患者临床研究 |
| Clinical study of Huangkui capsule combined with valsartan and Tripterygium Tripterygium wilfordii polyglycoside on early diabetic nephropathyYe Yuyan, Chen Liping, Yang Jing, kidney Department of Jinhua people |
| 投稿时间：2019-11-06 修订日期：2019-12-08 |
| DOI： |
| 中文关键词: 早期糖尿病肾病 雷公藤多苷 缬沙坦 黄葵胶囊 |
| 英文关键词:early diabetic nephropathy Tripterygium wilfordii glycoside valsartan Huangkui capsule |
| 基金项目: |
|
| 摘要点击次数: 594 |
| 全文下载次数: 3 |
| 中文摘要: |
| 目的：探讨黄葵胶囊联合缬沙坦和雷公藤多苷对早期糖尿病肾病患者临床研究。方法：选择我院于2017年5月至2019年5月期间收治的早期糖尿病肾病患者142例,依据随机表法随机分为观察组71例与对照组71例。对照组患者采用缬沙坦联合雷公藤多苷片治疗,观察组在对照组基础上结合黄葵胶囊。两组疗程均为12周。比较两组治疗疗效,治疗前后尿白蛋白排泄率(UAFR)和肾功能、炎症因子、转化生长因子-β1(TGF-β1)、肾损伤因子-1(Kim-1)和中性粒细胞明胶酶相关载脂蛋白(NGAL)变化,及不良反应。结果：观察组总有效率(91.55%)高于对照组(76.06%)(P<0.05)。观察组治疗后UAFR、Scr和BUN水平低于对照组(P<0.05)。观察组治疗后TNF-α、MCP-1和IL-6水平低于对照组(P<0.05)。观察组治疗后TGF-β1、Kim-1和NGAL水平低于对照组(P<0.05)。观察组不良反应(11.27%)少于对照组(28.17%)(P<0.05)。结论：黄葵胶囊联合缬沙坦和雷公藤多苷对早期糖尿病肾病患者疗效良好,可改善患者肾功能,减轻炎症反应,下调TGF-β1、Kim-1和NGAL水平,且无明显不良反应,用药安全性良好。 |
| 英文摘要: |
| Objective: The effect of Huangkui capsule combined with valsartan and Tripterygium glycoside on early diabetic nephropathy. Methods: The 142 patients with early diabetic nephropathy admitted to our hospital from May 2017 to may 2019 were randomly divided into observation group (71 cases) and control group (71 cases). The valsartan combined with Tripterygium glycoside tablets of control group were treated, and the observation group was treated with Huangkui Capsule on the basis of the control group. The two groups was 12 weeks. The UAFR and renal function, inflammatory factor, transforming growth factor-β1 (TGF-β1), renal injury factor-1 (KIM-1) and neutrophil gelatinase related apolipoprotein (NGAL) were compared before and after treatment. Results: the total effective rate of the observation group (91.55%) was higher than that of the control group (76.06%) (P<0.05). The observation group levels of TNF-α, MCP-1 and IL-6 were lower control group (P<0.05). The observation group levels of TGF-β1, Kim-1 and NGAL were lower control group (P<0.05). The adverse reactions in the observation group (11.27%) were less than those in the control group (28.17%) (P<0.05). Conclusion: Huangkui capsule combined with valsartan and Tripterygium wilfordii glycoside has a good therapeutic effect on early diabetic nephropathy, improve renal function, reduce the inflammatory response, and down regulate TGF-β1, KIM-1 and NGAL levers. There is no obvious adverse reaction, and the drug safety is good. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
